Is Interstitial Lung Disease Associated with Joint and Muscle Pain?
Yes, interstitial lung disease (ILD) is strongly associated with joint and muscle pain, particularly when ILD occurs in the context of systemic autoimmune rheumatic diseases (SARDs) such as rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease. 1
The Bidirectional Relationship
ILD as a Manifestation of Rheumatic Disease
ILD affects over 50% of adults with systemic sclerosis and is the leading cause of death in this population. 1 In these patients, joint and muscle pain are core features of the underlying autoimmune disease that also drives lung involvement.
In idiopathic inflammatory myopathies (including polymyositis and dermatomyositis), ILD occurs in approximately 65% of newly diagnosed cases and contributes to nearly 80% of mortality. 2 Arthritis and arthralgia are recognized risk factors for ILD development in these patients. 1
Arthritis is significantly more common in myositis patients with ILD compared to those without ILD. 3 This suggests that joint involvement and lung disease share common immunologic pathways in inflammatory myopathies.
Pain as a Direct Consequence of ILD
Pain prevalence reaches 61.9% in patients with ILD compared to only 25.3% in healthy controls, with chest pain being the most common location (46.1% of ILD patients). 4 This demonstrates that ILD itself generates significant pain independent of underlying rheumatic disease.
Patients with ILD and pain experience significantly impaired quality of life and higher rates of depression and anxiety compared to ILD patients without pain. 4 Pain intensity correlates with exposure history to ILD risk factors, six-minute walk distance ≥250 meters, and modified Medical Research Council dyspnea scores of 2-4. 4
Muscle Dysfunction in ILD
- Respiratory and lower limb muscle function are impaired in ILD patients, contributing to dyspnea, fatigue, and functional limitation. 5 While this represents muscle dysfunction rather than inflammatory myositis, it creates a clinical picture that includes muscle-related symptoms.
Key Risk Factors Linking Joint/Muscle Disease to ILD
Rheumatoid Arthritis
- High-titer rheumatoid factor and anti-CCP antibodies 1, 6
- High disease activity and elevated inflammatory markers 1
- Male sex, older age at onset, cigarette smoking 1
Idiopathic Inflammatory Myopathies
- Anti-synthetase antibodies (Jo-1, PL7, PL12, EJ, OJ, KS, Ha, Zo), anti-MDA-5, anti-Ku, anti-Pm/Scl, and anti-Ro52 positivity 1
- Mechanic's hands, arthritis/arthralgia, and ulcerating lesions 1
- ILD can present even when overt muscle disease is absent, making screening essential 2
Systemic Sclerosis
- Anti-Scl-70 positivity and antinuclear antibody with nucleolar pattern 1, 6
- Diffuse cutaneous subtype, male sex, African American race 1
- Early disease (first 5-7 years after onset) 1
Mixed Connective Tissue Disease
Clinical Implications and Screening Recommendations
When to Screen for ILD in Patients with Joint/Muscle Pain
The American College of Rheumatology conditionally recommends routine screening with pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) of the chest for all patients with systemic autoimmune rheumatic diseases at risk for ILD. 1, 6
Screening should occur regardless of respiratory symptoms, as ILD is often asymptomatic early in its course. 3 In one study, 65% of newly diagnosed polymyositis/dermatomyositis patients had ILD, many without respiratory complaints. 3
Patients with SSc require continuous surveillance, as new-onset ILD occurs at a rate of 3.83 cases per 100 person-years, with continuous detection up to 10 years from an initially negative baseline HRCT. 7
Screening Tests to Use
- Conditionally recommend: PFTs and HRCT chest 1, 6
- Conditionally recommend against: 6-minute walk test distance, chest radiography, ambulatory desaturation testing, or bronchoscopy for screening 1
- Strongly recommend against: surgical lung biopsy for screening purposes 1, 6
Monitoring Established ILD
- Conditionally recommend: PFTs, HRCT chest, and ambulatory desaturation testing 1
- Conditionally recommend against: 6-minute walk distance, chest radiography, or bronchoscopy 1
Critical Pitfalls to Avoid
Do not assume that well-controlled joint disease means low ILD risk—lung and joint involvement may evolve independently. 8 One study found only a correlation between ESR and ground-glass HRCT scores, with no correlation between lung function and other components of the DAS28 joint disease activity score. 8
Do not wait for respiratory symptoms before screening high-risk patients. 3 ILD frequently presents without dyspnea or cough in early stages, particularly in myositis. 2
Do not overlook pain as a significant symptom requiring management in ILD patients. 4 Pain contributes substantially to quality of life impairment and psychological distress. 4
Do not assume a single negative HRCT rules out future ILD development. 7 Patients with high-risk features (NYHA stage ≥2, muscle weakness, elevated inflammatory markers, SSc-specific autoantibodies) require ongoing surveillance regardless of disease duration. 7
Prognostic Considerations
New-onset ILD carries nearly double the mortality risk compared to patients who remain ILD-negative, even though the risk of progression is lower than in prevalent ILD diagnosed at baseline. 7
ILD represents the most serious pulmonary manifestation of rheumatic diseases and is a major cause of death in RA and the leading cause in systemic sclerosis. 1
Acute exacerbation, drug-induced pulmonary toxicity, infections, and tuberculosis represent potentially fatal complications requiring vigilant monitoring and a multidisciplinary approach. 9